Advancing a new generation of treatments for
central nervous system disorders
15 Apr 2013
NeurOp Receives Second Half of NIH Grant for Meeting Schizophrenia Research Mile ...
19 Feb 2013
NeurOp and Emory Scientists Target Cognitive and Mental Health Disorders
6 Sep 2012
NeurOp Receives $1 Million in NIH Funding for Ischemia Research
NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders,
including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of
N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling.
Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented
opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
Learn more about our science.